On May 22, 2013, Amarantus entered into a letter of intent to in-license a phase 2 drug candidate in L-Dopa-Induced Dyskinesia (LID) in patients with Parkinson's Disease from an undisclosed third party. Once the license is complete, Amarantus plans to initiate a phase 2b trial within 12 months.